GEN published a thoughtful coverage of last month's Bio-IT World plenary keynote where JT from Apheris presented a session on federated learning and fine-tuning for drug discovery.
Read the article: https://www.genengnews.com/gen-edge/bio-it-world-keynote-highlights-collaborative-intelligence-in-ai-driven-drug-discovery/
The AISB Network launches AISB Bind, a new federated initiative through which AbbVie, AstraZeneca, Bristol Myers Squibb, and Johnson & Johnson, will collaboratively train an AI model to predict how small molecules bind to their protein targets
Five pharma companies fine-tuned OpenFold3 Preview 2 across 20,167 private structures, none of which left their environments. On 1,056 held-out structures, high-quality interface predictions rose from 35.6% to 52.1% and correct ligand poses from 28.9% to 46.8%, ahead of every public model. A first for federated drug discovery.
GEN published a thoughtful coverage of last month's Bio-IT World plenary keynote where JT from Apheris presented a session on federated learning and fine-tuning for drug discovery.
NEWSLETTER
A quaterly briefing on operationalizing and customizing co-folding, ADMET and antibody developability models. Written by Robin Röhm, co-founder and CEO at Apheris.
